US Patent Issued to Genentech on July 8 for "Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies" (California Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,643, issued on July 8, was assigned to Genentech Inc. (South San Francisco, Calif.).

"Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies" was invented by Chi-Chung Li (South San Francisco, Calif.), Carol Elaine O'Hear (South San Francisco, Calif.) and Brendan Christian Bender (South San Francisco, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disord...